CARMEL, Ind., May 1, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company") a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today that it will report financial results for its first quarter 2024 ended March 31, 2024, on Thursday, May 9, 2024, before the market opens. The Company has scheduled a conference call that same day, May 9, 2024, at 9:00 a.m. ET, to review the results.
Interested parties can access the conference call via Internet webcast, which is available in the Investors section of the Company's website at https://ir.syrahealth.com/presentations/q1-2024-earnings-call.
Investors who would like to submit a question to be addressed on the call should email the question to This email address is being protected from spambots. You need JavaScript enabled to view it..
A webcast replay will be available in the Investors section of the Company's website at https://ir.syrahealth.com/presentations/q1-2024-earnings-call.
ABOUT SYRA HEALTH
Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit www.syrahealth.com.
For more information, please contact:
For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.41 |
| Daily Change: | -0.05 -9.89 |
| Daily Volume: | 178,254 |
| Market Cap: | US$3.680M |
December 02, 2024 November 26, 2024 October 29, 2024 September 13, 2024 August 08, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
